Blog
Applied DNA Announces Joint Development Agreement to Integrate Linea™ IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times STONY BROOK, N.Y., and NEEDHAM, M.A. – December 14, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Kudo Biotechnology (Kudo Bio), […]
APDN Announces Receipt of Linea™ DNA Follow-On Order for Cancer Diagnostic Application
STONY BROOK, N.Y. November 28, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea […]
Applied DNA Extends Application of Linea™ IVT Platform to saRNA (self-amplifying mRNA)
– Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA – – Extension Enabled by the Company’s Ongoing Platform Development and Optimization – STONY BROOK, N.Y. November 16, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced the expansion of its […]
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea™ DNA Platform
Preclinical Orders for Additional Customers Underway STONY BROOK, N.Y. November 9, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA (saRNA) template generated by its Linea™ DNA […]
APDN Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today’s mRNA Vaccines STONY BROOK, NY and ITHACA, NY / ACCESSWIRE / September 14, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain […]
APDN Advances Commercialization of Linea™ IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
– Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA Production – – Previously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciences – STONY BROOK, N.Y. – September 6, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, […]
LineaRx to Participate in Upcoming mRNA Industry Conferences
STONY BROOK, N.Y. – July 18, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its majority-owned biotherapeutics subsidiary, in upcoming mRNA industry conferences in Boston: “We are eager to introduce our newly launched Linea™ IVT platform and engage therapy developers […]
APDN Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT™ Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
– Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows – – Platform Currently Available Under Early Access Program – STONY BROOK, N.Y. – July 13, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA […]
White Paper: Next Generation Medicines, The Therapeutic Potential of linearDNA Delivered via Lipid Nanoparticle
A novel approach of using a DNA therapeutic platform with a Lipid Nanoparticle (LNP)-based delivery system and focused on veterinary vaccine applications has been evaluated and our preliminary results are reported in this white paper. The studies shown herein support the advancement of high-fidelity, PCR-produced linearDNA™ in vaccine applications, taking advantage of linearDNA’s rapid design, […]